EUS-guided RFA for Pancreatic Neoplasms

Last updated: August 30, 2023
Sponsor: Chinese University of Hong Kong
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neoplasms

Digestive System Neoplasms

Treatment

EUS-guided RFA

Clinical Study ID

NCT03218345
CRE-2015.531T
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Radiofrequency ablation has been used for treatment of solid neoplasms of the liver, lung, kidney and adrenal. Recently, EUS-guided RFA has become available and the device allows EUS-guided treatment of pancreatic neoplasms. The procedure has been shown to be feasible in the porcine pancreas and was used to treat small groups of patients that are not suitable for surgery suffering from pancreatic neoplasms.

The aim of the current study is to perform a multi-center prospective study on EUS-guided radiofrequency ablation (RFA) of solid pancreatic neoplasms. The hypothesis is that EUS-guided RFA is safe, feasible and effective for treating solid pancreatic neoplasms.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 18 years-old or above
  • Suffering from pancreatic neuroendocrine tumor or pancreatic ductal carcinoma (<5cm inlargest diameter) that was confirmed by fine needle aspiration cytology
  • Unsuitable for surgery, due to one (or more) of the following items:
  • ASA score > II*
  • An alternative advanced malignancy
  • Unsuitable for surgery upon expert's opinion for any other reason
  • Healthy individuals who are not keen for surgical resection
  • Eligible for endoscopic intervention
  • Written informed consent

Exclusion

Exclusion Criteria:

  • Coagulopathy (international normalized ratio >1.3, partial thromboplastin time greaterthan twice that of control), platelet count <50,000x103/uL
  • Pregnancy
  • Patients with a poor mental condition or mental retardation, unable to understand thenature and possible consequences of the study
  • Patients unwilling to undergo follow-up assessments
  • Patients with liver cirrhosis, portal hypertension and/or gastric varices.

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: EUS-guided RFA
Phase:
Study Start date:
August 01, 2016
Estimated Completion Date:
May 31, 2024

Study Description

RFA causes tissue destruction through the application of a high frequency alternating current, generating local temperatures above 60°C and leading to coagulative necrosis. The technique has been widely used in many solid organ tumors and has been shown to result in 5-year survival rates comparable to surgery. The technique is currently the standard therapy in hepatocellular carcinoma and colorectal pulmonary metastasis particular in patients that are not suitable for surgery.

This study is a multi-center prospective study involving four high volume international institutions. Consecutive patients suffering from pancreatic neuroendocrine tumors and pancreatic cancers would be recruited. EUS-guided RFA would be performed using a 19-gauge RFA electrode and a generator. The primary outcome would be the overall adverse events rate. Secondary outcomes include mortality, technical success rate, completion ablation rate, 1 & 3 year overall and disease-free survival.

Connect with a study center

  • Department of Surgery, Prince of Wales Hospital

    Hong Kong,
    Hong Kong

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.